Free tool
FAERS Monitor: Celontin
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 010596 or its brand name (Celontin, Methsuximide). Reports on generic versions are filed under their own applications.
Reports
182
Serious
107
59% of reports
Hospitalization
39
Death reported
2
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective25
- seizure21
- convulsion14
- dizziness13
- somnolence13
- feeling abnormal11
- generalised tonic-clonic seizure11
- off label use11
- fall9
- asthenia8
- drug interaction8
- fatigue8
- therapeutic product effect incomplete7
- condition aggravated6
- toxicity to various agents6
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 6 |
| 2005 | 3 |
| 2006 | 2 |
| 2007 | 2 |
| 2009 | 3 |
| 2010 | 7 |
| 2011 | 2 |
| 2012 | 9 |
| 2013 | 6 |
| 2014 | 6 |
| 2015 | 13 |
| 2016 | 10 |
| 2017 | 7 |
| 2018 | 21 |
| 2019 | 15 |
| 2020 | 15 |
| 2021 | 14 |
| 2022 | 14 |
| 2023 | 6 |
| 2024 | 9 |
| 2025 | 6 |
| 2026 | 6 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,977 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| generalised tonic-clonic seizureSignal | 11 | 76.9 | 43.3 | 750 |
| convulsionSignal | 14 | 28.3 | 17.1 | 343 |
| seizureSignal | 21 | 21.0 | 14.1 | 383 |
| therapeutic product effect incompleteSignal | 7 | 11.4 | 5.5 | 56 |
| somnolenceSignal | 13 | 7.5 | 4.4 | 67 |
| drug interactionSignal | 8 | 5.8 | 3.0 | 28 |
| feeling abnormalSignal | 11 | 5.3 | 3.0 | 35 |
| toxicity to various agentsSignal | 6 | 4.1 | 1.9 | 11 |
| fallSignal | 9 | 3.1 | 1.7 | 11 |
| dizzinessSignal | 13 | 3.0 | 1.8 | 16 |
| astheniaSignal | 8 | 2.5 | 1.2 | 6 |
| condition aggravated | 6 | 2.3 | 1.0 | 3 |
| drug ineffectiveSignal | 25 | 2.2 | 1.5 | 16 |
| off label use | 11 | 1.5 | 0.8 | 1 |
| fatigue | 8 | 1.2 | 0.6 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.